Abstract
Objectives
To determine 7 and 30-day mortality in consecutive patients with bacteraemic community-acquired pneumonia (CAP) and the association between predicted variables and likelihood of death.
Methods
From August 2007 to July 2011, demographic, clinical and microbiological data were prospectively collected on patients with bacteraemic CAP. Patients were followed until death, hospital discharge or recovery from infection. Univariate and multivariate analysis was performed to determine the association between predictor variables and 30-day mortality.
Results
7-day mortality was 61/252 [24.4 %, 95 % confidence interval (CI) 19.1–30.0 %] and by 30 days, this had risen to 77/252 (30.6 %, 95 % CI 24.9–36.6 %). In univariate analysis, factors associated with 30-day mortality were age, speciality within 48 h of admission, blood culture isolate and Charlson co-morbidity index (CCI). In multivariate analysis, age and CCI remained significantly associated. There was also a trend towards significance for meticillin-sensitive Staphylococcus aureus (MSSA) and Pseudomonas aeruginosa blood culture isolates compared to Streptococcus pneumoniae.
Conclusions
Overall, bacteraemic CAP was associated with high inpatient mortality. Because of their association with poor outcomes, patients with MSSA and P. aeruginosa bacteraemic CAP require further study.
References
Capelastegui A, España PP, Bilbao A, Gamazo J, Medel F, Salgado J, et al. Study of community-acquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care. J Infect. 2010;61:364–71.
Chetty K, Thomson AH. Management of community-acquired pneumonia in children. Paediatr Drugs. 2007;9:401–11.
Woodhead MA, MacFarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1987;1:671–4.
British Thoracic Society. Community-acquired pneumonia in adults in British Hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q J Med. 1987;62:195–220.
White RJ, Blainey AD, Harrison KJ, Clarke SK. Causes of pneumonia presenting to a district general hospital. Thorax. 1981;36:566–70.
MacFarlane JT, Finch RG, Ward MJ, Macrae AD. Hospital study of adult community-acquired pneumonia. Lancet. 1982;2:255–8.
Mongardon N, Max A, Bouglé A, Pène F, Lemiale V, Charpentier J, et al. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care. 2012;16:R155.
Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Resp Med. 2012;106:1124–33.
Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011;66:340–6.
Challen K, Bentley A, Walter D. Severity of illness assessment in community-acquired pneumonia. Thorax. 2011;66:351.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004;30:536–55.
Lin SH, Lai CC, Tan CK, Liao WH, Hsueh PR. Outcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniae. Epidemiol Infect. 2011;139:1307–16.
Kang CI, Song JH, Kim SH, Chung DR, Peck KR, Thamlikitkul V, et al. Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect. 2013;66:34–40.
Ruiz LA, Gómez A, Jaca C, Martínez L, Gómez B, Zalacain R. Bacteraemic community-acquired pneumonia due to Gram-negative bacteria: incidence, clinical presentation and factors associated with severity during hospital stay. Infection. 2010;38:453–8.
Sarkar TK, Murarka RS, Gilardi GL. Primary Streptococcus viridans pneumonia. Chest. 1989;96:831–4.
Park SY, Park HJ, Moon SM, Park KH, Chong YP, Kim MN, et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect Dis. 2012;12:308.
González C, Rubio M, Romero-Vivas J, González M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 1999;29:1171–7.
Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med. 2001;95:78–82.
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64:iii1–55.
McGregor JC, Rich SE, Harris AD, Perencevich EN, Osih R, Lodise TP, et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis. 2007;45:329–37.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
Andrews JM; BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 6). J Antimicrob Chemother. 2007;60:20–41.
Kunimasa K, Ishida T, Kimura S, Tanaka M, Kouyama Y, Yamashita S, et al. Successful treatment of fulminant community-acquired Pseudomonas aeruginosa necrotizing pneumonia in a previously healthy young man. Intern Med. 2012;51:2473–8.
Chuang TY, Lin CJ, Lee SW, Chuang CP, Jong YS, Chen WJ, et al. Rapidly fatal community-acquired pneumonia due to Klebsiella pneumoniae complicated with acute myocarditis and accelerated idioventricular rhythm. J Microbiol Immunol Infect. 2012;45:321–3.
Kwong JC, Chua K, Charles PG. Managing severe community-acquired pneumonia due to community methicillin-resistant Staphylococcus aureus (MRSA). Curr Infect Dis Rep. 2012;14:330–8.
Karampela I, Poulakou G, Dimopoulos G. Community acquired methicillin resistant Staphylococcus aureus pneumonia: an update for the emergency and intensive care physician. Minerva Anestesiol. 2012;78:930–40.
Nimmo GR. USA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2012;18:725–34.
Acknowledgement
I would like to thank my colleagues Dr. Sandra Lacey, Dr. Simon Namnyak, Dr. Lindsey Bain and Dr. Meredydd Nicholas who helped to collect these data.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Melzer, M., Welch, C. 30-day mortality in UK patients with bacteraemic community-acquired pneumonia. Infection 41, 1005–1011 (2013). https://doi.org/10.1007/s15010-013-0462-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-013-0462-7